In another analysis, rates of grade 3 hematologic toxicity were low in patients with or without prior 223Ra therapy (anemia, 1/20 [5%] vs. 3/29 [10%]; thrombocytopenia, 1/20 [5%] vs. 2/29 [7%]) (6), a result that again supports our findings, although we did not systematically assess hematologic toxicity in all patients during 177Lu-PSMA treatment—a limitation of our study. This evidence concerns the gene FOLH1 and anemia (phenotype).